A recent survey by Citi reveals a promising evolution in the field of electrophysiology: the pulsed field ablation (PFA) technique could surpass radiofrequency ablation by 2025. This study, conducted among specialized physicians, highlights the rapid rise of this innovative method, which could transform current practices in the treatment of atrial fibrillation. PFA, known for its advantages such as reducing damage to surrounding tissues, is garnering increasing interest among healthcare professionals, heralding a true revolution in cardiac ablation procedures.

A survey conducted by Citi Research anticipates that pulsed field ablation (PFA) could soon surpass radiofrequency ablation in the treatment of atrial fibrillation. The results indicate that by 2025, nearly 49% of AFib procedures could utilize PFA devices, compared to 39% this year. Meanwhile, the use of radiofrequency ablation is expected to decline, dropping from 40% to 33% of procedures. The growing popularity of PFA is attributed to its ability to reduce the risk of damage to surrounding tissues and shorten procedure times, making it an increasingly favored option among healthcare professionals.

According to a recent survey conducted by Citi, the pulsed field ablation (PFA) technique is on track to become the prevailing method for treating atrial fibrillation. This path to PFA dominance could occur more quickly than expected, with experts estimating it could account for nearly 49% of procedures by 2025. These findings underscore a significant transition in the cardiology sector, with a trend toward favoring approaches that minimize risks associated with surgical interventions.

evolution of trends in atrial fibrillation treatment

With the rise of new devices such as Medtronic’s PulseSelect, the landscape of treatment options is changing rapidly. Indeed, 72 physicians surveyed by Citi indicate that radiofrequency ablation, currently favored at 40%, is expected to see its share decrease to 33% in favor of PFA. This shift is also reflected in annual usage figures, where increased adoption of new ablation and electrophysiological mapping technologies is anticipated.

impact on the market and emerging technologies

Analysts predict that the combination of innovation and a growing need for less invasive procedures will propel PFA to the top of the market. PFA systems are designed to enable better precision while reducing the risk of complications. Companies like Boston Scientific and Johnson & Johnson are also introducing alternatives that are expected to contribute to this momentum. Ultimately, the use of mapping technologies could reach 70% within ablation procedures, underscoring the importance of real-time monitoring of cardiac activity.